NCT04396496View on ClinicalTrials.gov

Treatment of POEMS Syndrome With Daratumumab

PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

September 22, 2020

Primary Completion Date

August 29, 2023

Study Completion Date

October 16, 2023

Conditions
POEMS Syndrome
Interventions
DRUG

Daratumumab Injection

"DARA is a human monoclonal antibody that specifically recognizes the CD38 molecule that is expressed at a high level in a variety of hematological malignancies, including myeloma cells.~DARA injection will be given with oral lenalidomide for up to 12 four week cycles."

Trial Locations (1)

72205

University of Arkansas for Medical Sciences, Little Rock

All Listed Sponsors
collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

University of Arkansas

OTHER

NCT04396496 - Treatment of POEMS Syndrome With Daratumumab | Biotech Hunter | Biotech Hunter